Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Clear cell renal cell carcinoma (ccRCC) is a common genitourinary cancer associated with the development of abnormal tumor angiogenesis. Although multiple anti-angiogenic therapies have been developed, responses to individual treatment are highly variable between patients. Thus, the use of one-patient clinical trials has been suggested as an alternative to standard trials. We used a microfluidic device to generate organotypic primary patient-specific blood vessel models using normal (NEnC) and tumor-associated primary CD31+ selected cells (TEnC). Our model was able to recapitulate differences in angiogenic sprouting and vessel permeability that characterize normal and tumor-associated vessels. We analyzed the expression profile of vessel models to define vascular normalization in a patient-specific manner. Using this data, we identified actionable targets to normalize TEnC vessel function to a more NEnC-like phenotype. Finally, we tested two of these drugs in our patient-specific models to determine the efficiency in restoring vessel function showing the potential of the model for single-patient clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Nintedanib, a multi-tyrosine kinase inhibitor, decreased sprout number and length, enhancing vessel permeability.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Virumbrales-Muñoz et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sirolimus, a specific mTOR inhibitor, exhibited lower effectiveness and only restored permeability at high doses, despite increased cell toxicity.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Virumbrales-Muñoz et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Transcriptomics revealed a pro-angiogenic phenotype in tumor-associated vessels, showing patient-specific responses.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Virumbrales-Muñoz et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“Virumbrales-Munoz and colleagues further employed a microfluidic device to generate patient-specific blood vessel models, effectively replicating phenotypic differences between ccRCC tumor-associated and normal vessels (Virumbrales-Muñoz et al., 2020).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Virumbrales-Muñoz et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“The results underscore the capability of microfluidic vessel models for functional drug testing, enabling personalized screening and patient stratification in ccRCC.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Virumbrales-Muñoz et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Single-Cell Transcriptome Atlas of Murine Endothelial Cells
Kalucka, J., de Rooij, L. P. M. H., Goveia, J., Rohlenova, K., Dumas, S. J., Meta, E., Conchinha, N. V., Taverna, F., Teuwen, L.-A., Veys, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.015 · Cited by 1,351
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 937
Pusztaszeri, M. P., Seelentag, W., & Bosman, F. T. (2006) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.4a6514.2005 · Cited by 865
Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology
Augustin, H. G., & Koh, G. Y. (2017) · Science · doi:10.1126/science.aal2379 · Cited by 762
Research works printed but not linked: 1
- Rojiani MV, Alidina J, Esposito N. and Rojiani AM, Int J Clin Exp Pathol, 2010, 3, 775– 781. 21151391 PMC2993228
Cited by
Organs-on-a-chip models for biological research
Vunjak-Novakovic, G., Ronaldson-Bouchard, K., & Radisic, M. (2021) · Cell · doi:10.1016/j.cell.2021.08.005 · Cited by 248
“RNAsequencingofbloodvessels allowed selection of candidate drugs, ultimately leading to the testing of sirolimus and nintedanib (Virumbrales-Munoz et al., 2020).”
BackgroundA role for microfluidic systems in precision medicine
Ayuso, J. M., Virumbrales-Muñoz, M., Lang, J. M., & Beebe, D. J. (2022) · Nature Communications · doi:10.1038/s41467-022-30384-7 · Cited by 216
Self-citationLi, W., Zhou, Z., Zhou, X., Khoo, B. L., Gunawan, R., Chin, Y. R., Zhang, L., Yi, C., Guan, X., & Yang, M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202609 · Cited by 119
Organ-on-a-Chip Platforms for Drug Screening and Delivery in Tumor Cells: A Systematic Review
Gonçalves, I. M., Carvalho, V. M., Rodrigues, R. O., Pinho, D., Teixeira, S., Moita, A., Hori, T., Kaji, H., Lima, R. A., & Minas, G. M. H. (2022) · Cancers · doi:10.3390/cancers14040935 · Cited by 82
“[58] used a microfluidic device to recreate the blood vessel formation that occurs with the tumor growth.”
MethodBridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58
Simitian, G. S., Virumbrales-Muñoz, M., Sánchez‐de‐Diego, C., Beebe, D. J., & Kosoff, D. (2022) · Lab on a Chip · doi:10.1039/d2lc00352j · Cited by 56
Self-citationLugo-Cintrón, K. M., Ayuso, J. M., Humayun, M., Gong, M. M., Kerr, S. C., Ponik, S. M., Harari, P. M., Virumbrales-Muñoz, M., & Beebe, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103634 · Cited by 45
“Then, sprouts were counted, and each sprout was manually traced from the lumen using the segmented line tool from which the length was measured [28].”
MethodSelf-citationCancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 52
Microphysiological systems for solid tumor immunotherapy: opportunities and challenges
Abizanda-Campo, S., Virumbrales-Muñoz, M., Humayun, M., Mármol, I., Beebe, D. J., Ochoa, I., Oliván, S., & Ayuso, J. M. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-023-00616-x · Cited by 48
“The tumor vasculature is generally immature, with a tortuous structure and hyperpermeable vessels, characterized by poor pericyte coverage and an abnormal basement membrane 109 – 111 .”
BackgroundSelf-citationToward improved in vitro models of human cancer
Ayuso, J. M., Park, K.-Y., Virumbrales-Muñoz, M., & Beebe, D. J. (2021) · APL Bioengineering · doi:10.1063/5.0026857 · Cited by 40
Self-citationMao, Y., Mu, J., Zhao, J., Yang, F., & Zhao, L. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00458-2 · Cited by 38
From microfluidics to microphysiological systems: Past, present, and future
Virumbrales-Muñoz, M., & Ayuso, J. M. (2022) · Organs-on-a-Chip · doi:10.1016/j.ooc.2022.100015 · Cited by 35
Self-citationModels of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics
Shapiro, D. D., Virumbrales-Muñoz, M., Beebe, D. J., & Abel, E. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871252 · Cited by 28
Self-citationRecent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies
Ngo, T. K. N., Kuo, C., & Tu, T. (2023) · Biomicrofluidics · doi:10.1063/5.0108792 · Cited by 27
Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift
Lopez-Vince, E., Wilhelm, C., & Simón‐Yarza, T. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01580-3 · Cited by 26
Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy
Virumbrales-Muñoz, M., Ayuso, J. M., Loken, J. R., Denecke, K. M., Rehman, S., Skala, M. C., Abel, E. J., & Beebe, D. J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121454 · Cited by 20
Self-citationZhou, Y., Wu, Y., Paul, R., Qin, X., & Liu, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19453 · Cited by 21
Sánchez‐de‐Diego, C., Yada, R. C., Sethakorn, N., Geiger, P. G., Ding, A. B., Héninger, E., Ahmed, F., Virumbrales-Muñoz, M., Lupsa, N., Bartels, E., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08384-2 · Cited by 19
Self-citationLansche, C., Ladaigue, S., Gropplero, G., Zimmermann, N., Nurmik, M., Veith, I., Nguyen, M., Brosseau, S., Poté, N., Mordant, P., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403446 · Cited by 16
Recent advances in micro-physiological systems for investigating tumor metastasis and organotropism
Yoon, H., del Río, J. S., Cho, S. W., & Park, T. (2024) · Lab on a Chip · doi:10.1039/d3lc01033c · Cited by 13
Acoustofluidic Engineering of Functional Vessel-on-a-Chip
Wu, Y., Zhao, Y., Islam, K., Zhou, Y., Omidi, S., Berdichevsky, Y., & Liu, Y. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00925 · Cited by 14
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
In Vitro Model of Vascular Remodeling Under Microfluidic Perfusion
Nishikata, K., Doi, K., Kaneoya, N., Nakamura, M., & Futai, N. (2024) · Micromachines · doi:10.3390/mi16010014 · Cited by 8
Molecular sensors for detection of tumor-stroma crosstalk
Fuller, B. T., Buczynksi, E. M., Beshay, P. E., & Song, J. W. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.01.001 · Cited by 6
3D Printed Molds for Organ-on-a-Chip and Fluidics: PDMS-Based Rapid and Accessible PrototypingPreprint
Abbed, R. J., Cruz, E. I. Q., & Leggett, S. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.29.645830 · Cited by 5
Microfluidic and organ-on-a-chip approaches to model the tumor microenvironment
Bonnet, V., Angelidakis, E., Sart, S., & Baroud, C. N. (2025) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2025.100606 · Cited by 7
Polaki, U. S., Gilpin, T. E., Patil, A. T., Chiu, E., Baker, R., Liu, P., Pavletich, T. S., Seifi, M., Mañán-Mejías, P. M., Morrissey, J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187073 · Cited by 3
“Microdevices were fabricated using standard soft lithography as previously described (40–42).”
Self-citationMicrophysiological systems for metastasis research: a stepwise approach
Sharko, V., Ochoa, I., & Solanas, E. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01110-4 · Cited by 5
“The fibroblast monocul - ture is represented by the solid black bar [ 72, 99].”
Engineering a Microphysiological Model for Regenerative Endodontic Studies
Sanz‐Serrano, D., Mercadé, M., Ventura, F., & Sánchez‐de‐Diego, C. (2024) · Biology · doi:10.3390/biology13040221 · Cited by 2
“Microdevice setup and collagen injection were performed following the previously described protocol [23].”
MethodInfluentialA microfluidic device inspired by leaky tumor vessels for hematogenous metastasis mechanism research
Yin, S., Lu, R., Li, Y., Sun, D., Liu, C., Liu, B., & Li, J. (2023) · The Analyst · doi:10.1039/d2an02081e · Cited by 2
Microfluidic Models of the Tumor Microenvironment
Chang, C.-S., Holter, J. C., & Song, J. W. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00252 · Cited by 2
Pugh-Toole, M., Dawe, N., Smith, A., Boudreau, J. E., & Leung, B. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.08.511443 · Cited by 1
Preclinical Cancer Models for the Evaluation of Immunotherapies: From Cell Lines to Animal Models
Pezeshki, P. S., & Rezaei, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_206-1 · Cited by 1
Preclinical Cancer Models for the Evaluation of Immunotherapies: From Cell Lines to Animal Models
Pezeshki, P. S., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_206
Emerging Trends in In Situ Gellable Hydrogel
Kumari, L., Behera, A., & Ghosh, B. (2026) · Springer eBooks · doi:10.1007/978-981-95-6619-8_13
Modèles de vaisseaux sanguins sur puce pour l'étude des fonctions de la barrière endothéliale
Delannoy, E. (2021) · theses.fr (ABES) · doi:10.70675/c1aab157zdfc1z4179z9306zc6f4d4ffcd6f
Hypoxia-on-chip : from technological developments to biological applications
Bouquerel, C. (2023) · theses.fr (ABES) · doi:10.70675/d7d58b5dzd927z4235z8c54z8dbb6fd4757e · Cited by 1
Zaman, M., NAZARE, T., Sarkar, A., & Mirzapourshafiyi, F. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124696
Metadata
- Authors
- Virumbrales-Muñoz, M., Chen, J., Ayuso, J., Lee, M., Abel, E. J., & Beebe, D. J.
- Affiliations
- Department of Pathology and Laboratory Medicine
- University of Wisconsin–Madison (US)
- Department of Urology
- University of Wisconsin System (US)
- Corresponding author
- Beebe, David J.
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 20
- Issue
- 23
- Pages
- 4420-4432
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- PMC
- PMC8743028
- OpenAlex
- W3094590133
- Cited by
- 39
- References
- 51
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 6 · 2023: 8 · 2022: 11 · 2021: 4
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Lab on a Chip (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Wisconsin Carbone Cancer Center (P30 CA014520)
- NIH Clinical Center (Moonshot Grant NCI R33CA225281)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- clear cell renal cell carcinoma, patient-specific models, tumor angiogenesis, anti-angiogenic therapy, vascular normalization, CD31+ endothelial cells, microfluidics, angiogenic sprouting, vascular permeability, actionable targets
- MeSH terms
- Carcinoma, Renal Cell, Humans, Immunotherapy, Kidney Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.